The UK’s fastest academic supercomputer, based at the University of Cambridge, will be made available to artificial intelligence (AI) technology companies from across the UK, in support of the government’s industrial strategy.
Almost 30 years on from the discovery of the genetic defect that causes cystic fibrosis, treatment options are still limited and growing antibiotic resistance presents a grave threat. Now, a team of researchers from across Cambridge, in a major new centre supported by the Cystic Fibrosis Trust, hopes to turn fortunes around.
Five leading universities, including the University of Cambridge, have formed a partnership to develop and commercialise agritech research, in order to improve sustainability, increase productivity and contribute to global food security.
Researchers from the UK and Denmark have developed a new method to predict the physical stability of drug candidates, which could help with the development of new and more effective medicines for patients. The technology has been licensed to Cambridge spin-out company TeraView, who are developing it for use in the pharmaceutical industry in order to make medicines that are more easily released in the body.
Fairness, trust and transparency are qualities we usually associate with organisations or individuals. Today, these attributes might also apply to algorithms. As machine learning systems become more complex and pervasive, Cambridge researchers believe it’s time for new thinking about new technology.
What makes a city as small as Cambridge a hotbed for AI and machine learning start-ups? A critical mass of clever people obviously helps. But there’s more to Cambridge’s success than that.
A new design of algae-powered fuel cells that is five times more efficient than existing plant and algal models, as well as being potentially more cost-effective to produce and practical to use, has been developed by researchers at the University of Cambridge.
Kate Gross was just 36 years old when she died of cancer. Researchers at Cambridge – including her husband – are trying to ensure that others receive their diagnoses early enough to stop their cancer.
Human genome editing, 3D-printed replacement organs and artificial photosynthesis – the field of bioengineering offers great promise for tackling the major challenges that face our society. But as a new article out today highlights, these developments provide both opportunities and risks in the short and long term.
Andy Neely is Cambridge’s Pro-Vice-Chancellor for Enterprise and Business Relations, a role which oversees the University’s activities in innovation, commercialisation and entrepreneurship. After six months in the role, he sees an entrepreneurial ecosystem that may appear complex at first – but a deeper examination reveals a combination of knowledge, expertise, support and infrastructure that makes Cambridge one of the most enterprising and entrepreneurial cities in the world.